|
Attention APWCA Members & Stakeholders:
CALL TO ACTION
We need your voice once again!
A peer-reviewed manuscript accepted to be published in the Journal of Wound Care The hidden costs of limiting access: clinical and economic risks of Medicare’s future effective cellular, acellular and matrix-like products (CAMPs) Local Coverage Determination - has become available and makes it clear: Medicare’s forthcoming LCD “Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers,” set to take effect April 13, 2025, will cause significant harm to the patients we serve.
This policy imposes a rigid cap of eight CAMP applications over a 16-week episode of care regardless of clinical response. As providers on the front lines of wound care, we know this will:
- Worsen outcomes by increasing amputations, hospitalizations, and ED visits
- Restrict access for the most vulnerable Medicare beneficiaries
- Prevent physicians from exercising clinical judgment and practicing according to training
- Ignore critical real-world evidence that proves the value of these treatments
While the Alliance of Wound Care Stakeholders recently voiced support for the LCD, the APWCA strongly disagrees with its current form and urges Congress to intervene. Our patients deserve better.
|
